gsidgsidgsid
Welcome to the Global Solutions For Infectious Diseases Website
GSID Home Page
About Us
Our Programs
Support GSID
News & Publications
Contact Us
header

AIDSVAX® B/E Program: Clinical Trials

The following table represents the extensive clinical history of AIDSVAX®
B/E and the current studies where GSID serves as a manufacturing and product sponsor:

Study Protocol
Phase
Study Location
Clinical Trial Sponsor
Priming Vaccine
Study Status
VAX001
1/2
Thailand
VaxGen
AIDSVAX® B/E alone
Completed
VAX002
1/2
US
VaxGen
AIDSVAX® B/E alone
Completed
VAX003
3
Thailand
Bangkok Metropolitan Authority, Mahidol University and VaxGen
AIDSVAX® B/E alone
Completed
RV 135
1/2
Thailand
US Surgeon General / Dept. of the Army / WRAIR
Sanofi Pasteur ALVAC VCP1521
Completed
RV 144
3
Thailand
US Surgeon General / Dept. of the Army, NIH / NIAID, Thai MOPH, Mahidol University and the Royal Thai Army
Sanofi Pasteur ALVAC vCP1521
Completed

Study Protocol
Phase
Study Location
Clinical Trial Sponsor
Priming Vaccine
Study Status
RV305
2
Thailand
US Surgeon General / Dept. of the Army
Sanofi Pasteur ALVAC vCP1521
Completed
RV305A
2
Thailand
US Surgeon General / Dept. of the Army
AIDSVAX B/E boost only
Completed
RV306
2
Thailand
US Surgeon General / Dept. of the Army
Sanofi Pasteur ALVAC vCP1521
Completed
RV328
2
Thailand
US Surgeon General / Dept. of the Army
None / AIDSVAX B/E alone
Completed
HVTN 096/EV04
1
Switzerland
EuroVacc Foundation
EuroVacc NYVAC HIV-PT1, NYVAC HIV-PT4, IPPOX DNA-HIV-PT123
Completed*
HVTN097
1b
Republic of South Africa
NIH / NIAID / DAIDS
Sanofi Pasteur ALVAC vCP 1521
Completed*
HVTN105
1b
USA
NIH / NIAID / DAIDS
IPPOX DNA-HIV-PT123
Completed*
HVTN110
1
USA
PaxVax Inc.
PaxVax Ad4 mgag/Env C150
Completed
HVTN114
1
USA / Peru
NIH / NIAID / DAIDS
GeoVax MVA / HIV62B
Completed
HVTN121
1
USA
NIH / NIAID / DAIDS
AIDSVAX B/E alone
Ongoing
PXVX-HIV-100-001
1b
USA
PaxVax Inc.
PaxVax Ad4 mgag / Env C150
Ongoing
EV06
1
Uganda
EuroVacc Foundation
IPPOX DNA-HIV-PT123
Completed
EV07 
1
Uganda
EuroVacc Foundation
IPPOX DNA-HIV-PT123
Completed
PV1 (PrEPVacc)
2b
Uganda, South Africa, Tanzania, Mozambique
Imperial College, London
IPPOX DNA-HIV-PT123
In Planning

Study Status as of April 30, 2020

 


Additional Resources

  • AIDSVAX® Program: Overview
  • VaxGen Trials
  • RV144 Trials
  • Clinical Trials
  • AIDSVAX® Collaborators




    Print Friendly and PDF

 

 


GSID enters into an agreement to participate in the PrEPVacc Phase IIb clinical trial in four countries in Southern Africa
[more]